3-methyl-3-<3-(trifluoromethyl)phenoxy>but-1-yne | 130219-69-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl-3-<3-(trifluoromethyl)phenoxy>but-1-yne
• 英文别名: 1-trifluoromethyl-3-((2-methylbut-3-yn-2-yl)oxy)benzene；1-[(1,1-Dimethyl-2-propynyl)oxy]-3-(trifluoromethyl)benzene；1-(2-methylbut-3-yn-2-yloxy)-3-(trifluoromethyl)benzene
• CAS: 130219-69-1
• 化学式: C₁₂H₁₁F₃O
• 分子量: 228.214
• InChiKey: UGITXADQFNJTRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-methyl-3-<3-(trifluoromethyl)phenoxy>but-1-yne 在 potassium tert-butylate 、 sodium hydride 、 间氯过氧苯甲酸 、 N,N-二乙基苯胺 作用下， 以 四氢呋喃 为溶剂， 反应 57.5h， 生成 2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-7-(trifluoromethyl)-2H-1-benzopyran
  参考文献：
  名称：

  Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis

  摘要：

  A series of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans related to the potassium channel activator cromakalim have been prepared and evaluated for their relaxant activity in guinea pig isolated tracheal spirals. Several analogues show enhanced relaxant activity relative to cromakalim in this preparation and the rank order of potency for those substituents investigated at C-6 was CF3 greater than CN greater than C2H5 greater than aza greater than or equal to CH3. One compound, trans-3,4-dihydro-2,2-dimethyl-4-(2-oxopiperidin-1-yl)-7-(trifluor omethyl)-2H- 1-benzopyran-3-ol (24), was resolved into its two enantiomers and the activity was shown to reside essentially in the (+)-isomer, adding further support to the suggestion that the smooth muscle receptor for these potassium channel activators is stereoselective.

  DOI：

  10.1021/jm00173a019
• 作为产物：
  描述：

  2-甲基-3-丁炔-2-醇 、 alkaline earth salt of/the/ methylsulfuric acid 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 2.5h， 生成 3-methyl-3-<3-(trifluoromethyl)phenoxy>but-1-yne
  参考文献：
  名称：

  Improved synthesis of aryl 1,1-dimethylpropargyl ethers

  摘要：

  An efficient, general, and practical synthesis of aryl 1,1-dimethylpropargyl ethers has been developed.

  DOI：

  10.1016/s0040-4039(00)78231-1

文献信息

• Electrostatic Control of Regioselectivity in Au(I)-Catalyzed Hydroarylation
  作者：Vivian M. Lau、William C. Pfalzgraff、Thomas E. Markland、Matthew W. Kanan

  DOI：10.1021/jacs.6b11971

  日期：2017.3.22

  states. Here we investigate the effects of ion pairing on the regioselectivity of the hydroarylation of 3-substituted phenyl propargyl ethers catalyzed by cationic Au(I) complexes, which forms a mixture of 5- and 7-substituted 2H-chromenes. We show that changing the solvent dielectric to enforce ion pairing to a SbF6- counterion changes the regioselectivity by up to a factor of 12 depending on the substrate

  催化反应中的竞争途径通常涉及电荷分布非常不同的过渡态，但很少利用这种差异来控制选择性。在离子对复合物中，反离子靠近带电催化剂会产生强静电相互作用，可用于在能量上区分过渡态。在这里，我们研究了离子对对阳离子 Au(I) 配合物催化的 3-取代苯基炔丙基醚氢化芳基化的区域选择性的影响，该配合物形成 5-和 7-取代 2H-色烯的混合物。我们表明，改变溶剂电介质以加强与 SbF6-反离子的离子配对，根据底物结构，区域选择性最多可改变 12 倍。密度泛函理论 (DFT) 用于计算存在和不存在抗衡离子时推定的决定产物的异构过渡态 (ΔΔE‡) 之间的能量差。发现从高溶剂电介质中的未配对过渡态转换到低溶剂电介质中的离子配对过渡态 (Δ(ΔΔE‡)) 时 ΔΔE‡ 的变化与实验观察到的几种基板的选择性变化非常吻合。我们的计算表明，Δ(ΔΔE‡) 的起源在于过渡态的优先静电稳定，在离子对的情况下，反离子具
• Continuous Processing to Control a Potentially Hazardous Process:  Conversion of Aryl 1,1-Dimethylpropargyl Ethers to 2,2-Dimethylchromenes (2,2-Dimethyl-2<i>H</i>-1-Benzopyrans)
  作者：Ricardo J. Bogaert-Alvarez、Paul Demena、Gus Kodersha、Robert E. Polomski、N. Soundararajan、Steve S. Y. Wang

  DOI：10.1021/op0100504

  日期：2001.11.1

  The thermal Claisen rearrangement of 4-cyanophenyl 1,1-dimethylpropargyl ether (4) to 6-cyano-2,2-dimethylchromene (5), (6-eyano-2,2-dimethyl-2H-1-benzopyran), which is used in the synthesis of a potassium channel activator drug candidate, BMS-180448, created a significant process development issue. The resulting large heat release in this conversion posed not only a safety risk but could also cause product degradation if done in a batch-wise manner. The solution was to exploit the high surface-to-volume ratio of a plug-flow reactor that would maximize the heat transfer, thereby permitting tight and responsive temperature with better reaction control. In the course of successfully testing the plug-flow concept on "micro"-flow scale (gram quantity) and "kilo"-flow scale (similar to 10 kg), a generalized mathematical model capable of predicting the reaction performance based on the physical properties of any given plug-flow reactor was generated. The model provides requisite information to design and operate a plug-flow reactor of any size for this reaction. This model would optimize reaction conditions for an acquired reactor system capable of producing similar to7 kg/h of the dimethylchromene. Application of plug-flow reactor technology enabled production of high quality 2,2-dimethylchromenes in good yield (> 98 mol %) without the use of solvents and with virtually no waste streams.
• BUCKLE, DEREK R.;ARCH, JONATHON R. S.;FENWICK, ASHLEY E.;HOUGE-FRYDRYCH, +, J. MED. CHEM., 33,(1990) N1, C. 3028-3034
  作者：BUCKLE, DEREK R.、ARCH, JONATHON R. S.、FENWICK, ASHLEY E.、HOUGE-FRYDRYCH, +

  DOI：——

  日期：——
• Godfrey, Jollie D., Jr. Mueller Richard H., Sedergran Thomas C., Soundara+, Tetrahedron Lett, 35 (1994) N 35, S 6405-6408
  作者：Godfrey, Jollie D., Jr. Mueller Richard H., Sedergran Thomas C., Soundara+

  DOI：——

  日期：——
• [EN] TRIFLUOROMETHYL SUBSTITUTED COMPOUNDS AND A PHARMACEUTICAL COMPOSITION
  申请人：BEECHAM GROUP PLC

  公开号：WO1991009031A1

  公开（公告）日：1991-06-27

  (EN) A compound of formula (I) or, where appropriate, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein A1, A2, A3, A4, R1, R2, R3, R4 and Y are as defined herein; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound and composition in medicine.(FR) Composé ayant la formule (I) ou, dans les cas appropriés, un de ses sels ou un de ses solvates pharmaceutiquement acceptables. Dans la formule (I), A1, A2, A3, A4, R1, R2, R3, R4 et Y ont la définition décrite. Procédé de préparation de ce composé, composition pharmaceutique contenant ce composé, utilisation de ce composé et de cette composition en médecine.